Elevated Capital Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$302K Sell
2,351
-89
-4% -$10.4K 0.08% 208
2026
Q1
$293K Sell
2,440
-13,424
-85% -$1.55M 0.07% 224
2025
Q4
$1.67M Buy
15,864
+2,164
+16% +$203K 0.39% 68
2025
Q3
$1.15M Buy
13,700
+2,822
+26% +$232K 0.29% 90
2025
Q2
$976K Hold
10,878
0.27% 101
2025
Q1
$976K Buy
10,878
+866
+9% +$80.9K 0.27% 101
2024
Q4
$996K Buy
10,012
+2,654
+36% +$274K 0.27% 103
2024
Q3
$836K Buy
7,358
+1,763
+32% +$209K 0.22% 141
2024
Q2
$693K Buy
+5,595
New +$721K 0.19% 143

Other funds holding MRK

Elevated Capital Advisors's MRK Position: Q2 2026 in Review

Elevated Capital Advisors reduced its Merck (MRK) stake by 3.6% in Q2 2026, selling an estimated $10.4K and leaving 2,351 shares worth $302K. The position accounts for 0.08% of the portfolio, ranked #208.

Elevated Capital Advisors first reported a position in MRK in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.67M in Q4 2025. 3,847 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Elevated Capital Advisors held 2,351 shares of Merck worth $302K as of Q2 2026.
  • Elevated Capital Advisors sold 89 Merck shares in Q2 2026, an estimated $10.4K.
  • Merck made up 0.08% of Elevated Capital Advisors's portfolio in Q2 2026, its #208 holding.
  • Elevated Capital Advisors first reported a position in Merck in Q2 2024 and has held it in 9 quarters since.
  • Elevated Capital Advisors's Merck position peaked at $1.67M in Q4 2025.
  • 3,847 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.